Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, often characterized by a lack of effective therapeutic options and late-stage diagnosis. While approximately 90% of PDAC cases are driven by KRAS mutations, which have historically been difficult to target, a small subset of KRAS wild-type patients may harbor alternative, highly actionable drivers. This report presents a unique case of a 54-year-old male with KRAS wild-type PDAC featuring a "triple-threat" of actionable genomic alterations: novel somatic KANK1-ALK and UPP2-NTRK3 fusions, alongside a pathogenic germline BRCA1 mutation. These findings highlight the transformative potential of comprehensive next-generation sequencing (NGS) in identifying precision medicine pathways for patients with limited standard-of-care options.
Clinical Presentation and Methodology
The patient, a 54-year-old male, presented with a pancreatic mass and subsequently underwent a Whipple procedure followed by standard adjuvant chemotherapy. Given the aggressive nature of PDAC and the patient's KRAS wild-type status—a group known to harbor rare but targetable mutations—extensive molecular profiling was performed on the surgical specimen.
The methodology employed a multi-faceted diagnostic approach to ensure both discovery and validation:
- Next-Generation Sequencing (NGS): DNA from the tumor was sequenced using a comprehensive 539-gene panel on the Illumina NovaSeq6000 platform. Bioinformatics pipelines, including BWA-MEM for alignment and factera for fusion detection, were utilized to identify genomic rearrangements.
- Orthogonal Validation: To confirm the functional relevance of the NGS findings, researchers performed Immunohistochemistry (IHC) to assess protein expression and Fluorescence In Situ Hybridization (FISH) to visualize chromosomal rearrangements. This step is crucial to ensure that a DNA-level rearrangement results in a functional, oncogenic protein.
Molecular Profiling and Validation
The genomic analysis revealed two novel somatic fusions never before reported in solid tumors: KANK1-ALK (detected at a frequency of 9.87%) and UPP2-NTRK3 (detected at 4.01%). Additionally, a pathogenic germline BRCA1 p.Q12 mutation was identified.
A key insight from this case was the discrepancy between testing modalities. While the KANK1-ALK fusion was consistently detected across NGS, IHC, and FISH, the UPP2-NTRK3 fusion was only identified via NGS. This highlights a critical technical gap: complex intergenic rearrangements can sometimes be "invisible" to traditional protein-based or visual assays. The authors suggest that NGS is the superior tool for discovery in these complex cases, though RNA-based sequencing might be needed for definitive functional confirmation.
Clinical Implications and Discussion
The identification of the BRCA1 germline mutation led to a significant clinical pivot. Based on evidence from the POLO trial, which demonstrated the efficacy of PARP inhibitors in BRCA-mutated pancreatic cancer, the patient was transitioned to maintenance therapy with Olaparib. This discovery also carried significant implications for the patient's family, necessitating genetic counseling and screening for hereditary cancer risk.
While this single case study demonstrates the power of precision medicine, it also underscores the rarity of these events—ALK and NTRK fusions occur in less than 1% of PDAC cases. However, for the individual patient, finding these "needles in the haystack" is transformative. The co-occurrence of multiple targetable drivers suggests that some PDAC tumors may exhibit high genomic instability, offering multiple "doors" for targeted intervention. Systematic screening for these rare but actionable alterations could substantially improve the therapeutic outlook for a significant subset of PDAC patients in the era of precision oncology.
Summary updated